Ferring Pharmaceuticals, Rebiotix, (a Ferring company), and MyBiotics Pharma have announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age.
Currently bacterial vaginosis is treated with antibiotics, which can disrupt the vaginal microbiome, and it’s common for bacterial vaginosis to return following treatment.